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Translational research is conducted to achieve a predefined set of economic or societal goals. As a result, investment decisions on
where available resources have the highest potential in achieving these goals have to be made. In this paper, we first describe how
multicriteria decision analysis can assist in defining the decision context and in ensuring that all relevant aspects of the decision
problem are incorporated in the decision making process. We then present the results of a case study to support priority setting
in a translational research consortium aimed at reducing the burden of disease of type 2 diabetes. During problem structuring,
we identified four research alternatives (primary, secondary, tertiary microvascular, and tertiary macrovascular prevention) and
a set of six decision criteria. Scoring of these alternatives against the criteria was done using a combination of expert judgement
and previously published data. Lastly, decision analysis was performed using stochastic multicriteria acceptability analysis, which
allows for the combined use of numerical and ordinal data. We found that the development of novel techniques applied in
secondary preventionwould be a poor investment of research funds.The ranking of the remaining alternativeswas however strongly
dependent on the decision maker’s preferences for certain criteria.
1. Introduction
The difficulty of developing biomedical discoveries into new
medical technologies or therapies has beenwidely recognized
and is often referred to as the “bench-bed gap” or the “valley
of death” [1, 2]. Translational research aims to bridge this
gap by integrating the societal needs identified at the bedside
with the research done at the bench. It encompasses the
entire value chain from basic biomedical research, through
epidemiology, clinical testing, product development, policy
and regulatory compliance, and marketing. As a result, the
overall success of a translational research project is deter-
mined by a multitude of technological, clinical, economic,
and regulatory factors. All these factors need to be considered
when evaluating which of the available research strategies
are most likely to yield innovations that will eventually gain
widespread adoption in daily clinical practice. This makes
priority setting for translational research a complex problem
that requires decision makers to gather and synthesize exper-
tise from different fields.Without the use of a formal decision
support method, it is generally impossible to simultaneously
consider all aspects of such a decision problem, making it
likely that too much emphasis is put on a single outcome
of the translational research process. In such a setting, the
use of multicriteria decision analysis (MCDA) can assist
in structuring the problem and in making the decisions
justifiable and replicable, thereby increasing accountability
for public resources spend [3].
In the context of government-sponsored technology
development programs, MCDA has previously been applied
to support the selection of research and development projects
across different industries and focus areas [4, 5]. However,
these applications are not directly portable to research pri-
ority setting in biomedical translational research projects as
the healthcare industry has specific properties that were not
addressed in these studies. In particular, healthcare markets
are heavily regulated and public provision of goods and
services plays an important role in these markets. These
characteristics impose rather strict constraints with respect
to market penetration and price setting that already need to
be considered early during the translational research process.
In this paper, we demonstrate how these aspects can be
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Figure 1: Schematic overview of the application of multicriteria decision analysis for priority setting.
incorporated in a formal way by using MCDA for priority
setting at the start of a translational research project. We
illustrate this by means of a case study conducted within
the context of a translational research project aimed at the
prevention of type 2 Diabetes Mellitus (DM2) and its related
complications.
2. Application of MCDA to Research
Priority Setting in Biomedical Translational
Research Projects
Research priority setting for biomedical translational
research is a complex problem that requires decision makers
to consider a multitude of technological, clinical, economic,
and regulatory factors. In such situations, the use of a formal
decision support method encourages the incorporation of
views and knowledge from experts in different parts of the
value chain of biomedical research, thereby reducing the
possibility that at later stages in the product development
process problems are encountered that in hindsight could
already have been foreseen at the start of the project. It
can also ensure that all available information related to the
decision problem is incorporated into the decision making
process, thereby reducing the chance that the decision
focuses too much on a single or narrow set of aspects of the
problem. Within the framework of MCDA, this is achieved
by sequentially going through the following three phases:
problem structuring, scoring of the alternatives against the
criteria, and preference modeling (Figure 1). Each of these
phases is briefly described in the subsections below.
2.1. Problem Structuring. During problem structuring, the
different stakeholders involved in the decision making pro-
cess express their knowledge and views on the context of
the decision problem as well as their objectives regarding
the decision. Several formats and tools have been proposed
to support this idea generation process, including “Post-It”
sessions and various checklists and other aids to thinking
such as adopting different perspectives and identifying bar-
riers and constraints [3]. This divergent mode of thinking
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is followed by a convergent phase of idea structuring, in
which ideas are clustered and aggregated to arrive at a set
of decision alternatives (if not yet clearly defined at the start
of the process) and a set of criteria against which these
alternatives are to be evaluated. Depending on the decision
context, the definition of these criteria can to an extent
be informed by objective knowledge of relevant cause-and-
effect mechanisms from scientific literature or other sources.
However, the criteria should reflect the objectives of the
relevant decision makers and therefore should be derived
from discussions with the decision makers. Knowledge from
outside the decision maker group can be incorporated into
these discussions but should never dictate criteria by itself.
The output of the problem structuring phase is often a value
tree. This is a graphical representation of the hierarchical
ordering of the criteria.
2.2. Scoring of the Alternatives against the Criteria. The
next step is to score the alternatives against these criteria,
which is done at the lowest level of the value tree. For
some criteria (e.g., cost), it may be possible to assess the
performance of the alternatives numerically, whereas, for
others (e.g., quality), it may only be feasible to obtain an
ordinal ranking of the alternatives or to allocate them to
verbally defined levels of performance (e.g., poor, reasonable,
and excellent). How the alternatives are scored against the
criteria differs from decision context to decision context and
depends, amongst others, on the amount of data (e.g., results
from observational and/or experimental studies, output from
mathematical models, or expert opinion) that is available at
the start of the decision making process and on how many
resources one is willing to invest in the collection of more
precise measurements. As the information obtained in the
scoring phase can change the perspective on the decision
problem, it might be necessary to revert to the problem
structuring phase in order to incorporate these new insights
in the decision context. If this is not the case, the end of
the scoring phase concludes the formal specification of the
decision problem.
Based on the information in the scoring table, it is
sometimes possible to identify one or more alternatives for
which there is at least one other alternative that performs
better on all of the criteria included in the decision problem.
As it is never optimal to select one of these dominated
strategies, they can safely be eliminated from the set of
decision alternatives. If there is sufficient budget to fund
all the remaining strategies, the decision problem is solved,
meaning that the multicriteria decision making process can
be ended after the scoring phase. If not, the set of decision
alternatives needs to be further reduced by making value
trade-offs among the performance levels on the different
criteria. In such situations, the use of preference modeling
can assist in formalizing the decision makers’ preference
structures, thereby reducing the chance that the decision
focuses too much on a single aspect of the decision problem.
2.3. Preference Modeling. At the research priority set-
ting stage of a translational research project, the amount
of developmental uncertainty surrounding the conceived
product concepts is usually still enormous. As a result, a full
quantitative assessment of the expected clinical and economic
benefits from each of the identified decision alternatives is
generally not yet possible. It is therefore likely that for some
of the criteria the data in the scoring table are solely based
on expert opinion. As experts are often more comfortable
with producing rankings (e.g., the number of competitor
products is larger for alternativeA than for alternative B) than
with providing exact numerical estimates (e.g., there are 10
competitor products for alternative A and 6 for alternative B),
it is important that such ordinal data can be accommodated
in the preference modeling phase. For this reason, we will
focus in this section on describing SMAA-O [6], a variant
of the stochastic multicriteria acceptability analysis (SMAA)
method [7, 8] that has been developed for decision problems
where the data for some or all criteria is ordinal.
In SMAA-O, it is assumed that the decision maker’s
preference structure can be represented by means of a
mathematical function V(𝑥) that is constructed in such a
way that alternative 𝑖 is preferred over alternative 𝑗 if and
only if V(𝑥𝑖) > V(𝑥𝑗), where 𝑥𝑖 denotes the column of the
scoring table associated with alternative 𝑖. To simplify the
construction of V(𝑥), it is generally assumed that the criteria
satisfy the independence conditions for applying the additive
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so that the worst possible score on each criterion is assigned
a value of 0 and the best possible score is assigned a value
of 1, reflect the relative desirability of the different levels
of achievement on the individual criteria. For numerical
criteria, it is usually assumed that equal size ranges on the
measurement scales represent the same amount of value
to the decision maker, resulting in partial value functions
that are linear. For ordinal criteria, the use of such a linear
mapping between scale values and partial values is however
not directly suitable as the distance between ranks on an
ordinal scale is not known. In SMAA-O, this problem is
dealt with by randomly assigning the scale values on the
ordinal scale to partial values between 0 and 1, in such a way
that the rank order between the scale values is maintained.
Different ordinal to partial valuemappingsmay translate into
a different ranking of the decision alternatives as the overall
value associated with each of these alternatives may change.




, which describe the fraction of Monte Carlo iterations for
which alternative 𝑖 is ranked at place 𝑟. The pairwise winning
indices 𝑐
𝑖𝑗
describe the fraction of Monte Carlo iterations
for which alternative 𝑖 is ranked at a higher place than
alternative 𝑗. Missing or imprecise information with respect
to the values of the weights can be handled in a similar way
by sampling the weight vector from a uniform distribution in
the feasible weight space induced by the available preference
information.
3. Case Study
3.1. Decision Problem. The prediction and early diagnosis of
diabetes and diabetes-related cardiovascular complications
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(PREDICCt) project of the Center for Translational Molec-
ular Medicine (CTMM) was initiated to enhance the possi-
bilities for prevention of DM2 and associated complications
through the development of methodologies for molecular
diagnostics and molecular imaging of novel biomarkers
associated with the development of DM2 and its related
complications. DM2 is a complex disease with many genetic,
environmental, and behavioral determinants as well as bio-
logical pathways involved. Additionally, it is a chronic disease
that takes a long time to develop. As a result, there are many
different possible target applications for novel diagnostic and
imaging techniques. Not all target applications are however
equally likely to achieve the objectives of the project to the
same extent. As a result, a decision had to be made on the
priority setting for the investment of available resources.
3.2. Problem Structuring
3.2.1. Methods. Several discussion sessions were held with
various researchers from the PREDICCt project. During
these discussions multiple perspectives on the decision prob-
lem were suggested by participants and discussed in the
group. Based on these discussions, a set of alternatives was
defined.The business plan of CTMM, inwhich the stakehold-
ers in the project expressed their views and interests, served
as the starting point to define a set of criteria. All statements
concerning objectives were isolated from the business plan
and subsequently ordered and grouped.
3.2.2. Results. As the main aim of the PREDICCt project
was the prevention of DM2 and associated complications,
the decision alternatives were defined in the scope of the
preventivemedicine framework. Preventivemedicine is often
classified in three different levels. Primary prevention targets
those in whom the disease is not yet present, with the
aim to provide interventions to prevent the disease from
manifesting. Secondary prevention targets those who have
the disease but are not yet symptomatic, aiming to reduce
the morbidity through early treatment. Tertiary prevention
is aimed at those who are diagnosed with the disease
and enables the provision of interventions limiting further
morbidity caused by complications. Complications of DM2
are an important aspect in this case, as most of the burden of
the disease is caused by these complications [9].There are two
distinct categories of complications: microvascular (diabetic
nephropathy, neuropathy, and retinopathy) and macrovas-
cular (coronary artery disease, peripheral arterial disease,
and stroke) [10]. These two categories of complications
have distinct approaches to prevention, diagnosis, and care.
Therefore, it was considered important to make a distinction
between tertiary prevention aimed at microvascular compli-
cations and tertiary prevention aimed at macrovascular com-
plications. The 4 alternative research approaches identified
for the development of a novel biomarker technology in DM2
were thus as follows:
A biomarker technology applied to the general popula-
tion to
(1) select individuals eligible for interventions aimed at
preventing or delaying the onset of DM2 (primary
prevention),
(2) identify those with undiagnosed diabetes in order to
initiate treatment earlier (secondary prevention).
A biomarker technology applied to the population of
diagnosed DM2 patients to
(3) select those that would benefit from interventions
aimed at preventing or delaying microvascular com-
plications (tertiary prevention),
(4) select those that would benefit from interventions
aimed at preventing or delaying macrovascular com-
plications (tertiary prevention).
The structuring of objectives from the business plan resulted
in the identification of four main objectives: reduce the
burden of disease, reduce healthcare costs, increase economic
activity, and obtain a high academic profile.
The profile of academic output is to a large extent deter-
mined by the novelty and quality of scientific work presented.
This is not directly related to the decision alternatives at
hand,meaning that a high academic profile could be obtained
no matter what alternative is chosen. This objective was
therefore not considered relevant for the purpose of the
present analysis. For the other three objectives, we conducted
a literature review and a brainstorming session to identify
a set of factors that are important determinants of these
objectives and to identify potential barriers and constraints
that hinder their achievement. This resulted in the value tree
depicted in Figure 2.
In the healthcare technology market, the commercial
potential of a product is dependent on its clinical value and
its impact on the downstream healthcare consumption. The
extent of this relation is determined by the level of regula-
tion, which differs between jurisdictions as well as between
different parts of the healthcare system. For highly regulated
parts of the healthcare system, the impact of these factors on a
technology’s commercial potential can be assessed quantita-
tively by conducting a headroom analysis [11]. The rationale
behind this approach is that the estimated change in health
effects andhealthcare costs, both direct and indirect, resulting
from the implementation of a new technology determine the
value of the technology for society, and thereby themaximum
device-related cost which the use of this new product will
still be reimbursed. As this cost provides an upper-bound for
the price that the producer can charge for its product (the
principle of value-based pricing), the amount of headroom
available is a suitable proxy for the commercial potential of
a new medical technology. The upper arm of the value tree
therefore consisted of the following 3 determinants of the
commercial headroom available: the decrease in downstream
healthcare cost, the increase in quality-adjusted survival, and
the cost of the intervention associated with the diagnostic
or prognostic test. The 3 criteria forming the lower arm of
the value tree captured the likelihood that the availability
of a more accurate diagnostic or prognostic test will trigger
changes in how the healthcare system currently operates.


















Figure 2: Value tree of overall and lower-level objectives of the public-private partnership.
The feasibility of a treat-all option indicated the added value
of the ability to treat specific patients as opposed to treating all
patients. This provided an indication of the value stemming
from better discrimination or prediction. Furthermore, the
existence of high-quality competitor technologies, or lack
thereof, was considered a major driver for the success of a
novel technology to gainmarket share. Lastly, not all decision
alternativeswere considered equal in terms of the accessibility
of the market and the ease of implementation in the clinical
protocol. Technologies that readily fit within the practice
as outlined by current guidelines can be implemented with
relative ease. Contrarily, those that require a major change in
clinical or public health protocols, for example, the initiation
of a universal screening program, cannot fulfill their potential
until such changes are established.
3.3. Scoring of the Alternatives against the Criteria
3.3.1. Methods. For each of the decision alternatives, quan-
titative estimates of the decrease in downstream health-
care costs, the increase in quality-adjusted survival, and
the intervention costs were available in the literature. The
performance of the decision alternatives on these criteria
was therefore expressed numerically. The performance on
the other 3 criteria is strongly dependent on the type of
technology developed and can therefore not be quantified at
this stage. We therefore used expert opinion to formulate an
ordinal ranking of the decision alternatives with respect to
these criteria.
3.3.2. Results. The complete scoring matrix is shown in
Table 1. Estimates of the effects of primary prevention
of diabetes and tertiary prevention of macrovascular
complications on the reduction of downstream healthcare
costs, gain of quality-adjusted survival, and the costs of
interventions were based on a modeling study [12]. For
the primary prevention scenario, a lifestyle intervention
program in obese individuals was modeled, and for
the tertiary prevention of macrovascular complications,
a multifactorial treatment scenario combining intensive
glycemic control, cholesterol-lowering treatment, and
antihypertensive treatment was modeled. Estimates of
the reduction in downstream healthcare cost, gain of
quality-adjusted survival, and the costs of interventions for
tertiary prevention of microvascular complications were
based on a study that modeled the results of intensive
blood glucose control and use of ACE-inhibitors on
nephropathic complications [13]. As studies have found
that secondary prevention of DM2 has little to no effect on
downstream healthcare costs and quality-adjusted survival,
the performance of this alternative on these two criteria
was set equal to 0 [14]. However, in case screening is
performed and patients are discovered, they will be treated.
Therefore, the treatment costs of diabetes patients without
complications were included [15].
Two main aspects contributed to the ranking of the
feasibility to treat-all criterion: the budget impact and lack
of implementation of existing cost-saving interventions. Pri-
mary and secondary prevention were ranked as highest and
second highest as providing treatment to all individuals
eligible for screening would not be feasible due to budget
impact reasons. Within tertiary prevention, the microvas-
cular complication alternative was ranked lowest as cost-
saving interventions are readily available there but not yet
fully implemented [13]. The barriers to implement such
interventions must therefore first be overcome before the
improved risk stratification possibilities can be implemented.
Considering the performance of existing competing tech-
nologies, secondary prevention was ranked lowest. There,
the diagnosis of diabetes itself cannot be improved as the
disease is defined on measurements with the gold standard
(glucose measurements). Additionally, there are numerous
prescreening tools available that perform well and cost little
(risk questionnaires) [16]. As a result of the latter, primary
prevention was ranked second lowest. On the contrary, such
risk stratification tools are hardly available and perform
less well, for microvascular complications and to a lesser
extent macrovascular complications. Lastly, the primary and
secondary prevention settings of diabetes would necessitate
some form of screening. Such a public health program could
take years before being realized. This entails a serious prob-
lem for the implementation of any biomarker technology.
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healthcare costs Increasing C 658M C 0 C 73M C 312M
Added quality-adjusted survival Increasing C 280K C 0 C 1K C 80K
Cost of related intervention Decreasing C 792 C 663 C 155 C 561
Feasibility of treat-all option 2 1 4 3
Performance of existing tests 3 4 1 2
Ease of implementation 2 2 1 1
As diagnosed diabetes patients regularly consult a physician,
access to the patient is less problematic in the case of tertiary
prevention.
3.4. Preference Modeling
3.4.1. Methods. The partial value functions for the numer-
ical criteria were obtained by linearly rescaling the criteria
measurements to the interval [0, 1], with the values of 0 and
1 assigned to the worst and best levels of performance on
these criteria, respectively.The rankings of the alternatives on
the ordinal criteria were randomly mapped to partial values
between 0 and 1 consistent with these rankings by using the
SMAA-O method. With respect to the weights, we specified
three scenarios. First, we considered a base case scenario
in which no additional constraints on the values of the
weights were incorporated. The results of such a preference-
free analysis can be used to eliminate alternatives that always
fall short to at least one other alternative, irrespective of
the decision maker’s preferences. Second, we considered a
scenario where a large commercial headroomwas considered













. Lastly, we considered
a scenario where the previous preference statement was













analyses were conducted in R (version 3.0.1) using the smaa
(version 0.1.1) and hitandrun (version 0.2.2) packages that are
available from CRAN.
3.4.2. Results. For the preference-free analysis (Figure 3), we
found that secondary prevention has a very low (<0.05)
first rank acceptability index, making it unlikely to be
optimal for any decision maker. The optimality of the three
remaining strategies was however strongly dependent on
the decision maker’s preferences. Primary prevention was
very likely to be the best alternative when maximizing
the commercial headroom available is considered more
important than minimizing the barriers and constraints to
utilize this headroom (Figure 4). This is confirmed when
looking at the pairwise winning indices, which show that the
probability that primary prevention is preferred over tertiary
prevention of microvascular complications, the second best
alternative when improvement of commercial headroom
is favored, is 61% (Table 2). Contrarily, tertiary prevention
of microvascular complications and tertiary prevention of











Figure 3: Rank acceptability indices for the base case scenario.
macrovascular complications were clearly the preferred
strategies when having to deal with lesser obstacles is pre-
ferred over potential higher gains in terms of the objectives
stated by the stakeholders (Figure 5). However, as is shown by
the pairwise winning indices for this scenario (Table 3), the
provided preference information with respect to the values of
the weights was not precise enough to further discriminate
between these two remaining strategies.
4. Discussion
Priority setting for translational research is a complex prob-
lem that requires decision makers to gather and synthesize
expertise from different fields. In this paper, we have shown
through a case study how this process can be supported in a
formal way by applying MCDA.
The complete value chain in biomedical innovation poses
a complex and multifaceted problem for priority setting.
Additionally, ethics, public opinion, and politics come into
play when dealing with a healthcare setting. Under these
BioMed Research International 7










Primary prevention 0.96 0.61 0.65
Secondary prevention 0.04 0.07 0.02
Tertiary microvascular prevention 0.39 0.93 0.45
Tertiary macrovascular prevention 0.35 0.98 0.55









Primary prevention 0.88 0.35 0.31
Secondary prevention 0.12 0.18 0.12
Tertiary microvascular prevention 0.65 0.82 0.48
Tertiary macrovascular prevention 0.69 0.88 0.52











Figure 4: Rank acceptability indices when improvement of com-
mercial headroom is favored.
conditions, informal decision making will lead to the use
of intuitive and heuristic approaches as a decision maker
is unable to grasp the full complexity and trade-offs in a
decision [17]. Informal decisionmakingwill therefore depend
to a large extent on who is appointed to make the decision
and what the background expertise of the decision maker (or
group of decision makers) is, which would be undesirable
in case of large investments or investments of public funds.
The problem structuring phase of MCDA helps to overcome
this by encouraging the incorporation of expertise exogenous
to the decision makers. In our case study, this led to the
integration of two different perspectives on the decision
problem: that of the commercial headroom (based on the
improvement in diagnostic power of new technologies over











Figure 5: Rank acceptability indices when avoidance of barriers is
favored.
existing ones) and that of the barriers that new technologies
would face to access the market. After the scoring phase it
became apparent that the development of novel methods to
measure biomarkers that can be used in secondary prevention
of DM2 was certainly an unattractive research objective.
If decision makers were willing to invest in all remain-
ing three alternatives, the priority setting process could
be stopped after this phase. However, in order to explore
under which preferences the remaining alternatives would be
most attractive, we proceeded with the preference modeling
phase. A preference of decision makers for the maximization
of commercial headroom made the development of novel
methods to measure biomarkers used in primary prevention
the most attractive strategy. Alternatively, investing in novel
8 BioMed Research International
methods to measure biomarkers for tertiary prevention of
microvascular andmacrovascular complications was optimal
in case a safer strategy with fewer obstacles, but less gain,
would be preferred.
Early health economic modeling—the process of per-
forming an initial assessment of the costs and health effects
associated with a new medical technology before the tech-
nology has been fully developed—has recently been sug-
gested as a tool to inform new product development within
translational research projects [18–20]. However, given that
such calculations require very strict assumptions about how
a new technology performs in a specific clinical setting,
this approach cannot yet be applied when specific biological
targets still need to be identified. Other softer approaches
such as SMAA-O are therefore required to support research
priority setting at the start of a translational research
project, where outcomes are generally too uncertain to make
a full quantitative assessment of the expected return-on-
investment meaningful. Using MCDA for priority setting at
the beginning of a research project can facilitate decision
making further on in the research and development process.
For example, the data during the scoring phase can serve
as input for quantitative approaches such as headroom
analysis for product investment decision making [11] and
value-based pricing for market access [21]. We therefore see
SMAA-O or similar MCDA methods as a new instrument
in the early health technology assessment toolbox, being
one to be used at the very start of translational research
projects.
A strength of the SMAA-O methodology that we
employed in our case study is the possibility to combine ordi-
nal and numerical scoring of the alternatives. This allowed
us to make full use of the large amount of data available in
the scientific literature on costs and health burden related to
DM2, while still being able to incorporate expert judgment
on aspects for which no data was available. A limitation of
our study is that, apart from the scenarios considered, we did
not elicit any preference information on the weights from the
decisionmakers. Ordinal and ratio constraints on the weights
can however easily be incorporated in a SMAA analysis by
utilizing efficient weight generation techniques such as hit-
and-run sampling [22].
We have demonstrated in this paper how the prior-
ity setting in translational research may be approached
by applying MCDA. Future research is needed to fully
assess the applicability of this method at the very start
of a translational research project. Nonetheless, we are
confident that we have already made a convincing case
for formal decision making in priority setting in transla-
tional research. Our report may serve as a guide for future
decision makers, ultimately making the approach common
practice.
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